IPP Bureau
Lupin receives tentative approval from USFDA for Tolvaptan Tablets
By IPP Bureau - October 07, 2023
Tolvaptan Tablets (RLD Jynarque) had estimated annual sales of USD 287 million in the U.S. (IQVIA MAT August 2023)
Emmes acquires VaxTRIALS
By IPP Bureau - October 07, 2023
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
Cambrex completes US$38 million capacity expansion in High Point, North Carolina
By IPP Bureau - October 07, 2023
Amgen completes acquisition of Horizon Therapeutics
By IPP Bureau - October 07, 2023
Advances Amgen's mission to serve patients with rare disease medicines
Ministry of Ayush to launch special campaign 3.0,
By IPP Bureau - October 06, 2023
The Main campaign started from October 2
Ministry of Ayush inaugurates the conference on Homeopathy in Kolkata
By IPP Bureau - October 06, 2023
The World Homoeopathy Day commemorates the birth anniversary of Dr Samuel Hahnemann on 10th of April
Apollo launches Hyderabad's first homecare recovery program
By IPP Bureau - October 06, 2023
This integrated care offering is a step forward in our vision of providing an effective continuum of care for patients
Lonza further extends collaboration with major biopharmaceutical partner for manufacturing antibody-drug conjugates
By IPP Bureau - October 06, 2023
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
Asahi Kasei Pharma files application for approval to manufacture and sell Cresemba Capsule
By IPP Bureau - October 05, 2023
The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg
Marksans Pharma gets USFDA approval for Esomeprazole Magnesium delayed-release capsules
By IPP Bureau - October 05, 2023
This product is bioequivalent to the reference listed drug (RLD), Nexium 24 HR Delayed- Release Capsules, 2.0mg (OTC), of AstraZeneca Pharmaceuticals
Strides receives USFDA approval for Efavirenz, Emtricitabine & Tenofovir Disoproxil Fumurate tablets
By IPP Bureau - October 05, 2023
The approval adds to a list of products that Strides has approved in this therapeutic category through the PEPFAR pathway taking the total to 15 products
Emmes appoints Matt Bond as CFO
By IPP Bureau - October 05, 2023
His M&A background and experience with successful private-equity-backed companies will benefit the company’s growth and diversification strategy
Alembic received 6 USFDA approvals during Q2FY24
By IPP Bureau - October 05, 2023
The company has received six final approvals that includes Chlorpromazine Hydrochloride Tablets
Strides receives USFDA approval for Icosapent Ethyl capsules
By IPP Bureau - October 04, 2023
The product is bioequivalent and therapeutically equivalent to the RLD, Vascepa of Amarin
Lupin launches patient support program ‘Humrahi‘ for diabetes management
By IPP Bureau - October 04, 2023
India has the highest prevalence of diabetes globally, with an estimated 77 million people living with the condition and an expected 134 million cases by 2045
